DSS, Inc.
DSSDSS, Inc. is a technology company specializing in advanced 3D imaging and electronic design automation solutions. It provides products and services primarily for defense, aerospace, and industrial applications, focusing on high-performance visualization, imaging, and electronic component design and testing.
Company News
DSS, Inc. announced that its 2025 annual report (10-K) filed on March 31, 2026, includes a 'going concern' qualification from auditor HTL International LLC. The company clarified this announcement does not represent any change or amendment to its financial statements. DSS operates across product packaging, biotechnology, commercial lending, and s...
Impact Biomedical (IBO) shares surged 86.28% in after-hours trading to $0.77 following an SEC filing that disclosed amendments to its pending merger with Dr Ashleys Bio Labs Limited. The merger agreement was extended from March 31 to July 1, 2026, with revised share allocations. Dr Ashleys will issue 169.5 million shares (94.20% of total), while ...
DSS, Inc. (NYSE: DSS) announced the commencement of a public offering of Common Stock to raise capital for general corporate and working capital needs. Aegis Capital Corp. is serving as the sole book-running manager for the offering, which is subject to market conditions and SEC registration requirements.
DSS, Inc. announced that its subsidiary, Impact BioMedical Inc., has entered into a definitive merger agreement with Dr. Ashleys Limited, a global pharmaceutical company. The transaction will result in a newly formed combined entity traded on the NYSE American under the name 'Dr Ashleys Limited'.
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetoseâ„¢ technology platform. The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent # 11,898,184, entitled "Low Glycemic Sugar Compos...
